Compare WNW & EOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WNW | EOCN |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 3.6M |
| IPO Year | 2019 | 2013 |
| Metric | WNW | EOCN |
|---|---|---|
| Price | $2.37 | $3.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 51.5K | 4.4K |
| Earning Date | 11-04-2026 | 09-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $3.33 |
| 52 Week High | $13.52 | $3.80 |
| Indicator | WNW | EOCN |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 48.21 |
| Support Level | $2.30 | N/A |
| Resistance Level | $2.75 | $3.80 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 8.13 | 34.05 |
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.